growing gains

Growing Houston energy tech company plans to hire 150 new employees this year

Houston-based Corva, an AI-optimized analytics company, is in the process of hiring — a lot. Photo via corva.ai

While the oil and gas industry may be in store for sluggish growth in 2020, that's hardly the case for Houston-based energy tech startup Corva AI LLC.

Corva — which offers a real-time data analytics platform for drilling and completion (the stage when a well is prepared for production) — added 85 employees last year, mostly in Houston. And it's on track to make 150 new hires in 2020, including software developers, researchers, drilling engineers, and data analysts, says Courtney Diezi, the company's general manager. Two-thirds of this year's new hires will work in Houston, she says.

Diezi says the company's headcount currently stands at 120, with 100 employees in Houston and 20 in Ukraine.

Corva has expanded so much and so quickly that it outgrew its previous 11,000-square-foot office and is now at The Cannon, a coworking space and innovation hub in the Energy Corridor. It's set to move later this year to a new 40,000-square-foot space at The Cannon.

Founded in 2014 by CEO Ryan Dawson, Corva has raised just $3 million in outside funding to propel its growth.

"Our business has grown exponentially at the same pace as companies raising hundreds of millions in funding," Dawson says. "While the startup world has chased endless rounds of funding with the notion of either becoming a unicorn — or dying — we have focused on creating a company that cares deeply about our employees and a business that lasts 100 years."

Dawson describes Corva as the "modern brains" of drillings and completions. Oil and gas equipment sends millions of datapoints to Corva to help make complex decisions about drilling operations, she says. About 40 customers use Corva's technology.

In a 2019 news release, Dawson said Corva gauges its success "by the number of days we save on rigs, the costs we can quantifiably cut, and the number of catastrophic events we prevent." Corva's technology has saved millions of dollars for its customers and reduced the length of drilling projects by as many as three days, he said.

"Corva's challenge is to change the behavior of drillers who work for somebody else," the Journal of Petroleum Technology reported in 2019. "The fast-growing company has no shortage of users. Retaining those customers will require convincing oil companies that the real-time drilling data and analysis is creating enough value to justify the cost."

Corva's user-focused approach to developing technology helps attract and retain customers. Executives say they consider Corva a tech company that operates in the oil and gas sector rather than an oil and gas company that happens to develop software.

"Our software platform rivals Netflix and Twitter in terms of giant datasets and real-time processing," Diezi says. "Without a core expertise and founding team in software, we wouldn't be able to provide the amazing technology we do — it's too central to what we do. Corva is the perfect mixture of oil industry veterans and software whiz kids. Our customers love to work with us because we speak their language but provide world-class products solving hard problems."

As it continues to enlarge its workforce, Corva seeks to foster a workplace that embraces both oil industry veterans and software whiz kids.

"We want to be the most admired workplace in Houston, with a Google-like status both for our amazing products and our company culture," Diezi says.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted